Among 14 million commercially insured members, there were 8,447 members with an asthma biologic claim in 2Q2019 resulting in $0.84 PMPM cost, a 2.5% (24) Pharmacy benefit cost without asthma biologics.

Members were required to be new starts, defined as no asthma biologic claims in the pre-period and have ≥ 2 ICD-10 code J45% (asthma), ≥ 30 days apart during continuous enrollment. Thirty (2.0%) members newly started reslizumab, 84 (5.6%) benralizumab, and 50 (3.4%) omalizumab.

Average pharmacy cost without asthma biologic was $4,337, 80.1% (346) more than the average pharmacy cost for the pre-period. Average medical cost without asthma biologic was $7,436, 59.5% (50) more than the average medical cost for the pre-period.